s Eylea » DME Statistics/DR

An estimated 86 million adults have prediabetes and are at risk of developing diabetes1

Diabetes Affects 9.3% of the US Population (29.1 million
people) and Is the Seventh Leading Cause of Death in
the United States1

Diabetic Macular Edema (DME) Is the Most Common Cause of Vision Loss in
Patients With Diabetes2

The Incidence of Diabetes Has Increased Considerably Since 20003

The following charts show the change graphically. Higher rates of diabetes are noted by deepening colors.3

Newly diagnosed cases of diabetes increased 23% from 2000 to 2012.1,4 Rates of obesity increased nearly 40% from 2000 to 2012, and obesity is a risk factor for developing type 2 diabetes.5,6

Diabetic Retinopathy (DR)—a Common Retinal Complication of Diabetes2

DR Can Progress Toward Vision Loss

DR Is the Leading Cause of New Cases of Blindness Among U.S. Adults Aged 20 to 74 Years2

In diabetic eye disease, upregulation of vascular endothelial growth factor (VEGF) is a common cause of DME and plays a pivotal role in retinal microvascular complications7,8

DR Progresses Through a Spectrum of Disease Severity—From Mild Nonproliferative DR (NPDR) (With Few Signs or Symptoms) to Severe, Vision-Threatening Proliferative DR (PDR)2

DME may occur at any stage of DR2

The ETDRS-DRSS in VISTA and VIVID: Example of a ≥2-Step Improvement9

Coming Soon

IMPORTANT SAFETY INFORMATION
+
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
  • Intravitreal injections, including those with EYLEA, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering EYLEA. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately. Intraocular inflammation has been reported with the use of EYLEA.
  • Acute increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including with EYLEA. Sustained increases in intraocular pressure have also been reported after repeated intravitreal dosing with VEGF inhibitors. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
  • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA. The incidence in the DME studies from baseline to week 52 was 3.3% (19 out of 578) in the combined group of patients treated with EYLEA compared with 2.8% (8 out of 287) in the control group; from baseline to week 100, the incidence was 6.4% (37 out of 578) in the combined group of patients treated with EYLEA compared with 4.2% (12 out of 287) in the control group. There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.
  • Serious adverse reactions related to the injection procedure have occurred in <0.1% of intravitreal injections with EYLEA including endophthalmitis and retinal detachment.
  • The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.
IMPORTANT PRESCRIBING INFORMATION

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with

  • Neovascular (Wet) Age-related Macular Degeneration (AMD): The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in Patients with DME: The recommended dose is 2 mg administered by intravitreal injection every 4 weeks (monthly) for the first 5 injections, followed by 2 mg once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.

References

EYLEA and EYLEA4U are registered trademarks of Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road, Tarrytown, NY 10591
US-LEA-1934(1)

Share

You are about to leave the EYLEA® (aflibercept) Injection Website
by opening a new page. Regeneron does not control
the content of the Web site connected to this link.

Continue Cancel